Compare OVID & DHIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVID | DHIL |
|---|---|---|
| Founded | 2014 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 522.6M | 463.8M |
| IPO Year | 2017 | 1996 |
| Metric | OVID | DHIL |
|---|---|---|
| Price | $2.52 | $174.99 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $4.60 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 26.3K |
| Earning Date | 05-13-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 3.43% |
| EPS Growth | 3.90 | ★ 14.37 |
| EPS | N/A | ★ 17.91 |
| Revenue | $7,252,000.00 | ★ $145,201,729.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.34 | N/A |
| P/E Ratio | ★ N/A | $9.77 |
| Revenue Growth | ★ 1181.27 | 6.69 |
| 52 Week Low | $0.27 | $114.11 |
| 52 Week High | $3.11 | $175.00 |
| Indicator | OVID | DHIL |
|---|---|---|
| Relative Strength Index (RSI) | 45.92 | 70.47 |
| Support Level | $2.33 | $171.71 |
| Resistance Level | $2.72 | N/A |
| Average True Range (ATR) | 0.16 | 0.60 |
| MACD | -0.01 | 0.25 |
| Stochastic Oscillator | 32.46 | 99.72 |
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Diamond Hill Investment Group Inc sponsors, markets, and provides investment advisory and related services to various U.S. and foreign clients including mutual funds, separate accounts, and private investment funds. The company's objective is to fulfill a fiduciary duty to clients and secondary objectives to achieve an adequate long-term return for shareholders. The company generates its revenue from Investment advisory and fund administration fees.